Evidence map›Paper›PMID 30841931›Full record

ArticleJournal of experimental & clinical cancer research : CR2019

Protein kinase Ds promote tumor angiogenesis through mast cell recruitment and expression of angiogenic factors in prostate cancer microenvironment.

Wanfu Xu, Jiabi Qian, Fangyin Zeng, Songyu Li, Wenjing Guo, Liping Chen, Guihuan Li, Zhishuai Zhang, Qiming Jane Wang, Fan Deng

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 59 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Molecular Farming of Pembrolizumab and Nivolumab.International journal of molecular sciences · 2023
    Review
  11. Review
  12. Article
  13. Potential role for protein kinase D inhibitors in prostate cancer.Journal of molecular medicine (Berlin, Germany) · 2023
    Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Wanfu XuDepartment of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
Jiabi QianDepartment of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
Fangyin ZengDepartment of Clinical Laboratory, The Fifth Affiliated Hospital, Southern Medical University, Guangzhou, 510900, China.
Songyu LiDepartment of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
Wenjing GuoDepartment of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
Liping ChenDepartment of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
Guihuan LiDepartment of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
Zhishuai ZhangDepartment of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China.
Qiming Jane WangDepartment of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15261, USA.
Fan DengDepartment of Cell Biology, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China. fandeng@smu.edu.cn.
Southern Medical University · CNUniversity of Pittsburgh · US

Funding

A novel mitotic regulatory axis in neuroendocrine prostate cancerR01CA229431 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI WANG, QIMING JANE · 2019 to 2023
$1.8M
Joint Research Fund for Overseas Chinese Scholars and Scholars in Hong Kong and Macao 81328020National Natural Science Foundation of China 81272852National Natural Science Foundation of China 81472407National Natural Science Foundation of China 81672540National Natural Science Foundation of China 81772761NCI NIH HHS R01 CA229431Science and Technology Project of Guangzhou 201607010351Science and Technology Project of Guangzhou 210707010303
6 · The paper itself

Abstract

backgroundMast cells are being increasingly recognized as critical components in the tumor microenvironment. Protein Kinase D (PKD) is essential for the progression of prostate cancer, but its role in prostate cancer microenvironment remains poorly understood.

methodsThe expression of PKD, mast cells and microvessel density were examined by IHC. The clinical significance was determined by statistical analyses. The biological function of PKD and the underlying mechanisms were investigated using in vitro and in vivo models.

resultsPKD2/3 contributed to MCs recruitment and tumor angiogenesis in the prostate cancer microenvironment. Clinical data showed that increased activation of PKD at Ser744/748 in prostate cancer was correlated with mast cell infiltration and microvascular density. PKD2/3 silencing of prostate cancer cells markedly decreased MCs migration and tube formation of HUVEC cells. Moreover, PKD2/3 depletion not only reduced SCF, CCL5 and CCL11 expression in prostate cancer cells but also inhibited angiogenic factors in MCs. Conversely, exogenous SCF, CCL5 and CCL11 reversed the effect on MCs migration inhibited by PKD2/3 silencing. Mechanistically, PKD2/3 interacted with Erk1/2 and activated Erk1/2 or NF-κB signaling pathway, leading to AP-1 or NF-κB binding to the promoter of scf, ccl5 and ccl11. Finally, PKD-specific inhibitor significantly reduced tumor volume and tumor growth in mice bearing RM-1 prostate cancer cells, which was attributed to attenuation of mast cell recruitment and tumor angiogenesis.

conclusionsThese results demonstrate a novel PKDs function that contributes to tumor angiogenesis and progression through mast cells recruitment in prostate cancer microenvironment.

Indexed as

Angiogenic ProteinsAnimalsCell Line, TumorChemokine CCL11Chemokine CCL5Gene Expression Regulation, NeoplasticHumansHuman Umbilical Vein Endothelial CellsMaleMAP Kinase Signaling SystemMast CellsMiceNeovascularization, PathologicPhosphorylationPromoter Regions, GeneticProstateAngiogenic ProteinsCCL11 protein, humanCCL5 protein, humanChemokine CCL11Chemokine CCL5KITLG protein, humanProtein Kinase Cprotein kinase DRELA protein, humanStem Cell FactorTranscription Factor AP-1Transcription Factor RelAAngiogenesisMast cells(MCs)Prostate cancerProtein kinase D(PKD)

Identifiers

PMID30841931
PMCPMC6404326
OpenAlexW2928621333

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.